HCA Healthcare (HCA)
Health Care · healthcare facilities / hospitals · NYSE
HCA Healthcare is one of the nation's largest operators of acute care hospitals and related health services, leveraging a massive footprint to provide comprehensive medical care.
What HCA Healthcare does
HCA Healthcare is a leading provider of healthcare services in the United States, operating a extensive network of hospitals and related healthcare facilities. The company provides a broad range of inpatient and outpatient medical services, including general and specialized surgery, diagnostic services, and emergency care. It focuses on delivering high-quality, patient-centered care through its integrated system of hospitals, freestanding surgery centers, and other healthcare delivery locations.
Themes: healthcare services, hospitals and surgery centers, outpatient care, managed care integration
Fundamentals
- Price$445.01 as of 2026-10-08 close
- Market cap$98.7B as of 2026-04-27 (share count; price 2026-10-08)
- 1-year return+4.4% 2025-10-08 close $426.27 → 2026-10-08 close $445.01
- P/E14.90 as of 2026-10-08
- Net margin+9.0% FY2025, SEC XBRL
- Debt / equity125.80 as of 2026-09-03
- Revenue growth (YoY)+7.3% as of 2026-09-03
- Revenue CAGR (3y)+7.9% SEC XBRL
- Beta0.24 as of 2026-09-03
- Last reported earnings2026-07-24 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.7%; 6-year non-decreasing per-share dividend streak (SEC XBRL).
How HCA compares in its sector
- price-to-earnings ratiobottom 25% 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldmiddle range 72 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, HCA's dividend was covered by reported results (earnings payout 10%, free-cash-flow payout 9%). This describes past coverage, not a forecast.
- Earnings payout10% dividends / net income
- Free-cash-flow payout9% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How HCA Healthcare looks technically
HCA Healthcare (HCA) is trading 0.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 93 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It just made a new 20-day high, its first since 2026-04-27, pushing above its recent trading range. It is 20.0% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move.
Trend
8
| Distance from the 200-day | it is trading 0.4% below its 200-day average, the long-term trend line — a long-term downtrend | -0.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $419.61 | $419.61 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $446.67 | $446.67 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 13 calendar days ago — the swings before that are what the structure reading is measured on | 13 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 420. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 93 trading days ago — a "death cross", a bearish long-term signal | 93 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend), though buyers have been pushing harder than sellers lately — pressure, not a trend | 18.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 62.8 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($420.00 to $446.48) — its "stochastic" reading is 94 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 94.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $556.52 | $556.52 |
|---|---|---|
| From the 52-week high | it is 20.0% below its 52-week high (its highest price of the past year) | -20.0% |
| Above the 52-week low | it is 25.7% above its 52-week low (its lowest price of the past year) | +25.7% |
| Below the 52-week high | it is 20.0% below its highest point of the past year | 20.0% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-04-27, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day high, its first since 2026-04-27, pushing above its recent trading range | 1 session |
| All-time high | its highest closing price on record is $556.52 (set on 2026-03-12) | $556.52 |
| Given back of the 52-week move | over the past year its closes ranged ($361.32 to $545.13), and it has recovered around half of its fall from last year’s high — 46% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $474.91 to $480.80. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 45.5% |
| From the all-time high | it is 20.0% below its all-time high | -20.0% |
| Nearest price level | it is trading 1.3% above a support level at $439.28 — a price it turned at four times since 2025-10-07, most recently on 2026-08-24. Since 2024-10-08 it has 11 such levels below the current price and 5 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.3% |
| All-time low | its lowest closing price on record is $17.03 (set on 2011-08-09) | $17.03 |
| Above the all-time low | it is 2513.1% above its all-time low | +2,513% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move | 2nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $11.91 between its high and its low — about 2.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $11.91 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $419.17 and $442.38 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $419.17 – $430.77 – $442.38 |
| Typical daily range (% of price) | its price moves about 2.7% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.7% |
| Stretch from the 200-day average | it is trading 0.1 daily ranges below its 200-day average price (0.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.1 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.77× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
|---|
Price gaps
1
| Gap at the open | it opened on 2026-10-08 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.5% |
|---|
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +2.96% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 9.7 percentage points (the stock gained 10.7% while the market gained 1.0%) | +9.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 4.6 percentage points (the stock gained 8.4% while the market gained 3.8%) | +4.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 25.5 percentage points (the stock lost 8.0% while the market gained 17.5%) | -25.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 10.6 percentage points (the stock gained 4.4% while the market gained 15.0%) | -10.6% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a fresh 20-day high, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 6.7% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 4.9% of the share price. | +6.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 2% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $436.14 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +2.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% above the average price paid since it last reported on 2026-07-14 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $410.42 — a volume-weighted average of daily closes over 62 sessions, not a true tick-by-tick VWAP. | +8.4% |
Price levels it has turned at before
HCA last closed at $445.01 on 2026-10-08. Since 2024-10-08 it has turned at 11 prices below its last close and 5 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $439.28 | Support | 1.3% below the last close | turned there four times · 2025-10-07 to 2026-08-24 |
| $461.11 | Resistance | 3.6% above the last close | turned there four times · 2025-12-17 to 2026-04-02 |
| $420.23 | Support | 5.6% below the last close | turned there 7 times · 2024-10-18 to 2026-09-25 |
| $478.55 | Resistance | 7.5% above the last close | turned there twice · 2025-10-30 to 2025-12-26 |
| $409.85 | Support | 7.9% below the last close | turned there twice · 2025-08-21 to 2025-10-14 |
| $487.85 | Resistance | 9.6% above the last close | turned there twice · 2026-01-06 to 2026-01-15 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $420.00.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $470.36 and $501.48 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $420.00.
This reading has stood for 5 trading days, since 2026-10-02.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.96 mean, 1=Strong Buy…5=Strong Sell) — 22 analysts
- Mean price target$459.27 range $380.00 – $579.00; median $475.50
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for HCA
- Consensus EPS estimate$6.65 next reporting period, as of 2026-10-09
- Estimate change, 30 days-$0.04436 (-0.7%) from $6.70, on 2026-09-04, 35-day window
- Readings revised upward0% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Fluctuations in reimbursement rates from government and private payers","Challenges in recruiting and retaining skilled nursing and medical staff","Exposure to significant professional liability and medical malpractice claims"]
What changed in the latest 10-Q
AI-assisted comparison of HCA's 10-Q filed 2026-07-28 against the prior one filed 2026-04-29.
Management's Discussion & Analysis (MD&A)
- Added:
- In item (2), the newer filing (filed 2026-07-28) refers to 'federal and state-based health insurance exchanges (the "Exchanges")' while the older filing (filed 2026-04-29) refers to 'federal and state-based health insurance marketplaces'.
- Removed:
- In item (2), the older filing (filed 2026-04-29) refers to 'federal and state-based health insurance marketplaces' while the newer filing (filed 2026-07-28) refers to 'federal and state-based health insurance exchanges (the "Exchanges")'.
- Reworded:
- In item (5), the newer filing (filed 2026-07-28) states 'attain expected levels of patient volumes and revenues and service mix' while the older filing (filed 2026-04-29) states 'attain expected levels of patient volumes and revenues'.
- In item (6), the newer filing (filed 2026-07-28) states 'the impact of reductions or other changes in Medicare' while the older filing (filed 2026-04-29) states 'possible reductions or other changes in Medicare'.
Risk Factors
- Added:
- In the filing dated 2026-07-28, the share repurchase disclosure states repurchases of 4,752,930 shares at an average price of $414.25 per share for the quarter ended June 30, 2026.
- In the filing dated 2026-07-28, the share repurchase table covers the period April 1, 2026 through June 30, 2026, with monthly details for April, May, and June 2026.
- In the filing dated 2026-07-28, the approximate dollar value available under the publicly announced plans or programs is listed as $8.738 billion (April 30, 2026), $7.921 billion (May 31, 2026), and $7.210 billion (June 30, 2026).
- In the filing dated 2026-07-28, a quarterly dividend of $0.78 per share is declared on July 23, 2026, payable September 30, 2026 to stockholders of record on September 16, 2026.
- In the filing dated 2026-07-28, Exhibit 4.1 through 4.6 are added, relating to Supplemental Indentures No. 54, 55, and 56 dated April 30, 2026, and Forms of 4.700% Senior Notes due 2031, 5.000% Senior Notes due 2033, and 5.300% Senior Notes due 2036.
- In the filing dated 2026-07-28, the Exchange Act is defined parenthetically as "(the “Exchange Act”)" in Item 5(c).
- Removed:
- In the filing dated 2026-04-29, the share repurchase disclosure states repurchases of 3,156,569 shares at an average price of $497.63 per share for the quarter ended March 31, 2026.
- In the filing dated 2026-04-29, the share repurchase disclosure references two authorizations: January 2025 and January 2026, both for up to $10 billion, and notes the January 2025 authorization was fully utilized during the first quarter of 2026.
- In the filing dated 2026-04-29, the share repurchase table covers the period January 1, 2026 through March 31, 2026, with monthly details for January, February, and March 2026.
- In the filing dated 2026-04-29, the approximate dollar value available under the publicly announced plans or programs is listed as $10.101 billion (January 31, 2026), $9.682 billion (February 28, 2026), and $9.179 billion (March 31, 2026).
- In the filing dated 2026-04-29, a quarterly dividend of $0.78 per share is declared on April 23, 2026, payable June 30, 2026 to stockholders of record on June 16, 2026.
- In the filing dated 2026-04-29, Exhibit 10.1 is listed, relating to the HCA Healthcare, Inc. 2026 Executive Officer Performance Excellence Program (filed as Exhibit 10.1 to the Company's Current Report on Form 8-K filed on February 25, 2026).
- In the filing dated 2026-04-29, the Exchange Act is referenced without a parenthetical definition in Item 5(c).
- Reworded:
- The share repurchase program description changed: the filing dated 2026-04-29 describes two authorizations (January 2025 and January 2026, both for up to $10 billion) and repurchases under both; the filing dated 2026-07-28 describes only the January 2026 authorization for up to $10 billion and repurchases under that authorization.
- The Item 5(c) disclosure changed: the filing dated 2026-07-28 refers to "the three months ended June 30, 2026" and includes a parenthetical definition of the Exchange Act; the filing dated 2026-04-29 refers to "the three months ended March 31, 2026" and omits that parenthetical.
- The signature date changed from April 29, 2026 (older filing) to July 28, 2026 (newer filing).
- The interactive data description in Exhibit 101 changed to reference the quarter ended June 30, 2026 (newer filing) versus the quarter ended March 31, 2026 (older filing).
- Notes:
- The Risk Factors section text itself (the incorporation-by-reference statement) is identical in both filings: both state there have not been any material changes to the risk factors previously disclosed in the annual report on Form 10-K for the year ended December 31, 2025.
- The provided section text includes other items in the quarterly report beyond Risk Factors (Items 2, 5, 6, and Signatures), so the comparison covers those included sections as well.
- This is an AI-assisted source comparison, not legal or investment advice.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
Most recent open-market transaction: 2026-02-18. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about HCA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 10 matched disclosures for HCA from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding HCA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 23,531,479
- Reported value $9,174,688,821
reported quarterly holdings change (2026-03-31 → 2026-06-30): 1 new, 2 increased, 3 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about HCA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
HCA had 6,479,985 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
HCA had 2.92% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.52 days to cover at the same settlement.
- Reported short interest (shares) 6,479,985
- Short interest (% of shares outstanding) 2.92%
- Prior settlement (shares) 6,135,558
- Reported change 5.61%
- Days to cover (reported) 4.52
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Tenet Healthcare (THC)
- Universal Health Services (UHS)
- Community Health Systems (CYH)
- Lifepoint Health
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare HCA vs…
HCA Healthcare is found in…
Frequently asked questions
What does HCA Healthcare (HCA) do?
HCA Healthcare is a leading provider of healthcare services in the United States, operating a extensive network of hospitals and related healthcare facilities. The company provides a broad range of inpatient and outpatient medical services, including general and specialized surgery, diagnostic services, and emergency care. It focuses on delivering high-quality, patient-centered care through its integrated system of hospitals, freestanding surgery centers, and other healthcare delivery locations.
What sector is HCA Healthcare (HCA) in?
HCA Healthcare (HCA) is classified in the Health Care sector. Its industry is healthcare facilities / hospitals. It trades on NYSE.
Does HCA pay a dividend?
Yes — HCA Healthcare (HCA) pays a dividend, with an indicated yield of about 0.73% and 6-year non-decreasing per-share dividend streak (SEC EDGAR XBRL) (market data, as of 2026-09-03). Informational only — not financial advice.
Who are HCA Healthcare's (HCA) competitors?
Notable peers of HCA Healthcare (HCA) include Tenet Healthcare, Universal Health Services, Community Health Systems and Lifepoint Health. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in HCA?
Yes — we hold 10 matched STOCK Act disclosures for HCA from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is HCA Healthcare (HCA) overbought or oversold right now?
HCA Healthcare (HCA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on HCA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.